<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133315</url>
  </required_header>
  <id_info>
    <org_study_id>232-001</org_study_id>
    <secondary_id>KF 02-050/04</secondary_id>
    <nct_id>NCT00133315</nct_id>
  </id_info>
  <brief_title>TNFalfa Blocking Treatment of Spondylarthropathies</brief_title>
  <official_title>TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to establish a Danish cohort of spondylarthropathy (SpA) patients
      who are being treated with TNFalfa blockers. By following the TNFalfa blocking treated
      patients the researchers want to identify better biomarkers for disease activity and disease
      progression. In addition, the researchers want to identify predictors for disease
      progression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>Spondylarthropathies</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriatic Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18 years old

          -  Spondylarthropathies according to the European Spondylarthropathy Study Group (ESSG)
             criteria

          -  Sacroiliitis by X-ray or magnetic resonance imaging (MRI)

          -  Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)&gt;3

          -  No signs of tuberculosis (TB)

          -  Sufficient contraception

        Exclusion Criteria:

          -  Wish of pregnancy or nursing

          -  Previous treatment with TNFalfa blocker

          -  Disease-modifying anti-rheumatic drugs (DMARDs) other than methotrexate (MTX) later
             than 4 weeks before inclusion

          -  Steroid treatment later than 4 weeks before inclusion

          -  Immunosuppressing agents later than 4 weeks before inclusion

          -  Severe infections within 3 months

          -  HIV-infection

          -  Active hepatitis B and C

          -  Active or latent TB

          -  Severe chronic diseases

          -  Heart insufficiency (New York Heart Association [NYHA] 3 and 4)

          -  Malignancy

          -  Systemic lupus erythematosus (SLE) or SLE-like disease

          -  Abuse of narcotics or alcohol

          -  Major psychiatric disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inge Juul Soerensen, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital, Dept. of Rheumatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Gentofte</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graasten Gighospital</name>
      <address>
        <city>Graasten</city>
        <zip>6300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horsens Sygehus</name>
      <address>
        <city>Horsens</city>
        <zip>8700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2005</study_first_posted>
  <last_update_submitted>April 9, 2007</last_update_submitted>
  <last_update_submitted_qc>April 9, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylarthropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

